Rice Hall James & Associates LLC Purchases Shares of 300,650 Urogen Pharma $URGN

Rice Hall James & Associates LLC purchased a new stake in Urogen Pharma (NASDAQ:URGN) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 300,650 shares of the company’s stock, valued at approximately $11,064,000. Rice Hall James & Associates LLC owned approximately 0.62% of Urogen Pharma at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Persistent Asset Partners Ltd bought a new position in shares of Urogen Pharma during the second quarter worth about $66,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares in the last quarter. Osaic Holdings Inc. boosted its position in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after acquiring an additional 5,571 shares in the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider owned 119,763 shares of the company’s stock, valued at $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,222 shares of company stock worth $892,661 in the last three months. Company insiders own 4.80% of the company’s stock.

Urogen Pharma Stock Up 1.9%

Shares of Urogen Pharma stock opened at $49.14 on Tuesday. The stock has a market cap of $2.40 billion, a P/E ratio of -24.82 and a beta of 1.57. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $49.67. The business’s 50 day moving average is $38.96 and its 200-day moving average is $28.36.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. On average, sell-side analysts expect that Urogen Pharma will post -0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

URGN has been the topic of a number of research reports. TD Cowen boosted their price objective on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $44.00 target price on shares of Urogen Pharma in a research report on Wednesday, July 15th. Oppenheimer lifted their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $50.38.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.